AMY MURDOCK: Open Payments
NPI 1811535149 · NEDERLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 35 payments from 9 companies in 2025. Trend: 2023 $517 · 2024 $555 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $167 |
| Novo Nordisk Inc | 18 | $162 |
| ABBVIE INC. | 4 | $85 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Galderma Laboratories, L.P. | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| BIOTRONIK NRO, Inc. | 1 | $17 |
| Abbott Laboratories | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: CAPLYTA, Wegovy, Rybelsus, UBRELVY, VRAYLAR, ZEPBOUND, BREZTRI, FARXIGA.
Industry payments across TX — which companies pay providers there.
